Sarcoidosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Sarcoidosis - Pipeline Review, H2 2014', provides an overview of the Sarcoidosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sarcoidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcoidosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Sarcoidosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sarcoidosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sarcoidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Sarcoidosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sarcoidosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Sarcoidosis Overview 6 Therapeutics Development 7 Pipeline Products for Sarcoidosis - Overview 7 Pipeline Products for Sarcoidosis - Comparative Analysis 8 Sarcoidosis - Therapeutics under Development by Companies 9 Sarcoidosis - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Sarcoidosis - Products under Development by Companies 12 Sarcoidosis - Companies Involved in Therapeutics Development 13 Auven Therapeutics Management L.L.L.P 13 Celgene Corporation 14 FirstString Research, Inc. 15 Johnson & Johnson 16 PharmaIN Corporation 17 Therametrics holding AG 18 Sarcoidosis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 apremilast - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CC-220 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 DasKloster-0182-01 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 eprodisate disodium - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 golimumab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 PGC-VIP - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Synthetic Peptide for Sarcoidosis - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 thymopentin - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Sarcoidosis - Recent Pipeline Updates 42 Sarcoidosis - Dormant Projects 56 Sarcoidosis - Discontinued Products 57 Sarcoidosis - Product Development Milestones 58 Featured News & Press Releases 58 Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring 58 Mar 09, 2011: MondoBIOTECH's Sarcoidosis Drug Thymopentin Receives Orphan Drug Designation From FDA 58 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 61 Disclaimer 61
List of Tables Number of Products under Development for Sarcoidosis, H2 2014 7 Number of Products under Development for Sarcoidosis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Sarcoidosis - Pipeline by Auven Therapeutics Management L.L.L.P, H2 2014 13 Sarcoidosis - Pipeline by Celgene Corporation, H2 2014 14 Sarcoidosis - Pipeline by FirstString Research, Inc., H2 2014 15 Sarcoidosis - Pipeline by Johnson & Johnson, H2 2014 16 Sarcoidosis - Pipeline by PharmaIN Corporation, H2 2014 17 Sarcoidosis - Pipeline by Therametrics holding AG, H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Sarcoidosis Therapeutics - Recent Pipeline Updates, H2 2014 42 Sarcoidosis - Dormant Projects, H2 2014 56 Sarcoidosis - Discontinued Products, H2 2014 57
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.